SEC Filings

SEC Filings

Filing date	Description	Form	View
May 10, 2016	Quarterly report which provides a continuing view of a company's financial position	10-Q	View HTML 0001193125-16-585715.pdf 0001193125-16-585715.rtf 0001193125-16-585715.xls EX-101.INS - XBRL INSTANCE DOCUMENT
May 06, 2016	Report of unscheduled material events or corporate event	8-K	View HTML 0001193125-16-580486.pdf 0001193125-16-580486.rtf 0001193125-16-580486.xls
May 06, 2016	Statement of changes in beneficial ownership of securities	4	View HTML 0001209191-16-118161.pdf 0001209191-16-118161.rtf
May 06, 2016	Statement of changes in beneficial ownership of securities	4	View HTML 0001209191-16-118156.pdf 0001209191-16-118156.rtf
May 06, 2016	Statement of changes in beneficial ownership of securities	4	View HTML 0001209191-16-118165.pdf 0001209191-16-118165.rtf
May 06, 2016	Statement of changes in beneficial ownership of securities	4	View HTML 0001209191-16-118169.pdf 0001209191-16-118169.rtf
May 06, 2016	Statement of changes in beneficial ownership of securities	4	View HTML 0001209191-16-118172.pdf 0001209191-16-118172.rtf
May 06, 2016	Statement of changes in beneficial ownership of securities	4	View HTML 0001209191-16-118195.pdf 0001209191-16-118195.rtf
Apr 01, 2016	Official notification to shareholders of matters to be brought to a vote ("Proxy")	DEF 14A	View HTML 0001193125-16-526118.pdf 0001193125-16-526118.rtf 0001193125-16-526118.xls
Mar 28, 2016	Annual report which provides a comprehensive overview of the company for the past year	10-K	View HTML 0001193125-16-519841.pdf 0001193125-16-519841.rtf 0001193125-16-519841.xls EX-101.INS - XBRL INSTANCE DOCUMENT

Data provided by Kaleidoscope.

For investor inquiries, please contact:

ReShape Lifesciences Investor Contact:
Thomas Stankovich
Chief Financial Officer
949-276-6042
ir@ReShapeLifesci.com

Investor Contacts:
Rx Communications Group
Michael Miller
917-633-6086
mmiller@rxir.com

PRINT PAGE

EMAIL PAGE